IL146082A0 - Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains - Google Patents

Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains

Info

Publication number
IL146082A0
IL146082A0 IL14608200A IL14608200A IL146082A0 IL 146082 A0 IL146082 A0 IL 146082A0 IL 14608200 A IL14608200 A IL 14608200A IL 14608200 A IL14608200 A IL 14608200A IL 146082 A0 IL146082 A0 IL 146082A0
Authority
IL
Israel
Prior art keywords
fibrosis
antagonism
treatment
receptor chains
receptor
Prior art date
Application number
IL14608200A
Other languages
English (en)
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23164976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146082(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of IL146082A0 publication Critical patent/IL146082A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
IL14608200A 1999-04-28 2000-04-28 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains IL146082A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/301,808 US6664227B1 (en) 1996-03-01 1999-04-28 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
PCT/US2000/011612 WO2000064944A1 (en) 1999-04-28 2000-04-28 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains

Publications (1)

Publication Number Publication Date
IL146082A0 true IL146082A0 (en) 2002-07-25

Family

ID=23164976

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14608200A IL146082A0 (en) 1999-04-28 2000-04-28 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
IL146082A IL146082A (en) 1999-04-28 2001-10-21 Use of il-13 antagonist - for the production of a drug to treat tissue loosening

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146082A IL146082A (en) 1999-04-28 2001-10-21 Use of il-13 antagonist - for the production of a drug to treat tissue loosening

Country Status (16)

Country Link
US (2) US6664227B1 (https=)
EP (2) EP1173484B1 (https=)
JP (3) JP4988988B2 (https=)
KR (1) KR100862931B1 (https=)
CN (1) CN1348465A (https=)
AT (1) ATE515513T1 (https=)
AU (1) AU780991B2 (https=)
BR (1) BR0010061A (https=)
CA (1) CA2370306C (https=)
DK (1) DK1173484T3 (https=)
HU (1) HU230582B1 (https=)
IL (2) IL146082A0 (https=)
MX (1) MXPA01011023A (https=)
NZ (1) NZ515464A (https=)
PT (1) PT1173484E (https=)
WO (1) WO2000064944A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
MXPA01006006A (es) 1998-12-14 2004-08-12 Genetics Inst Cadena receptora de citocina.
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
US7541040B2 (en) * 2001-12-04 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Serivces Chimeric molecule for the treatment of th2-like cytokine mediated disorders
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
ES2365210T3 (es) * 2002-06-14 2011-09-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
EP1713441A2 (en) * 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
EP1734970B1 (en) 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
MXPA06014091A (es) * 2004-06-04 2007-01-31 Wyeth Corp Inhibidores de proteinas regiii como substancias terapeuticas para el asma.
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
WO2006124451A2 (en) * 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
JP2010502224A (ja) * 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
EA200970588A1 (ru) * 2006-12-15 2009-12-30 Сентокор Орто Байотек Инк. Способы и композиции для лечения патологий, связанных с опосредуемым il-4 или il-13 фиброзом
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CN101318013B (zh) * 2008-07-17 2013-04-10 四川大学 Il-4在制备治疗慢性肝纤维化的药物组合物中的用途
EA201170357A1 (ru) 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
PT2953948T (pt) 2013-02-07 2017-12-12 Scifluor Life Sciences Inc Antagonistas de integrina fluorada
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
TW201628647A (zh) * 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
AU2015346150B2 (en) * 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
BR112017023432A2 (pt) 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
CN105052892A (zh) * 2015-07-20 2015-11-18 山东省齐鲁干细胞工程有限公司 一种无dmso的冷冻保护剂与冷冻保存卵巢的方法
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
WO2021249555A1 (en) * 2020-06-12 2021-12-16 Beijing Vdjbio Co., Ltd. Fusion polypeptide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1997033913A1 (en) 1996-03-13 1997-09-18 Zymogenetics, Inc. Cytokine-receptor expressed in testis cells
WO1997047741A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
EP0812913A3 (en) 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules

Also Published As

Publication number Publication date
HUP0200862A3 (en) 2004-11-29
HU230582B1 (hu) 2017-01-30
JP2003527311A (ja) 2003-09-16
NZ515464A (en) 2004-02-27
HUP0200862A2 (hu) 2002-07-29
EP2123674A1 (en) 2009-11-25
BR0010061A (pt) 2003-02-25
JP2011078432A (ja) 2011-04-21
AU780991B2 (en) 2005-04-28
EP1173484B1 (en) 2011-07-06
DK1173484T3 (da) 2011-10-03
MXPA01011023A (es) 2002-05-06
PT1173484E (pt) 2011-09-29
KR20020026426A (ko) 2002-04-10
US7282206B2 (en) 2007-10-16
CN1348465A (zh) 2002-05-08
AU4680500A (en) 2000-11-10
WO2000064944A1 (en) 2000-11-02
KR100862931B1 (ko) 2008-10-13
CA2370306C (en) 2014-06-17
CA2370306A1 (en) 2000-11-02
IL146082A (en) 2014-08-31
JP2014087345A (ja) 2014-05-15
JP4988988B2 (ja) 2012-08-01
US6664227B1 (en) 2003-12-16
EP1173484A1 (en) 2002-01-23
ATE515513T1 (de) 2011-07-15
US20050096268A1 (en) 2005-05-05
EP1173484A4 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
HK1047236A1 (zh) 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
AU7316601A (en) Methods for treating inflammation-mediated conditions of the eye
MY131911A (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2h-benzopyran or dihydrobenzodioxin) carboxamide derivatives
IL146482A0 (en) Tek antagonists
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PL369535A1 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
ZA200108446B (en) Novel method of treatment.
MXPA02007232A (es) Derivados aminados de dihidro-1,3,5-triazina y sus ojos terapeuticos.
MXPA03008853A (es) Antagonistas de ccr5 utiles para el tratamiento del sida.
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
IL151646A0 (en) Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
HK1040184A1 (zh) 治療青光眼之組合療法
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
WO2002096420A3 (en) Method for treating nerve injury caused by surgery
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
AU5756100A (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
AU3290200A (en) Treatment agents for textiles, method of producing same and their use
WO2002011713A3 (en) Methods of treating bone cancer and the pain associated therewith using endothelin antagonists